文献速递前列腺癌

根治性前列腺切除术后放疗联合无、短期或长期雄激素剥夺治疗的随机试验:RADICALS-HD三向比较结果(NCT00541047)

Randomised Trial of No, Short-term, or Long-term Androgen Deprivation Therapy with Postoperative Radiotherapy After Radical Prostatectomy: Results from the Three-way Comparison of RADICALS-HD (NCT00541047).
PubMed 文献 · Eur Urol · 2024-08-31

RADICALS-HD三向比较纳入492例根治性前列腺切除术后需放疗且同意随机分配至无、6个月或24个月雄激素剥夺治疗(ADT)的患者,主要终点为无转移生存(MFS),中位随访9.0年。总体MFS无差异(logrank p=0.98),长期ADT对比无ADT的风险比=0.948(95%CI 0.54-1.68)。作者认为在适合三种ADT时长的患者中未见加用ADT的改善证据。

要点

  • 中位随访9.0年,无、短期、长期ADT三组总体无转移生存无差异(logrank p=0.98)。
  • 长期对比无ADT的风险比=0.948(95%CI 0.54-1.68),未达统计学显著。
  • 10年后无转移生存率:无ADT组80%、短期组77%、长期组81%。

核心结论

  • 在根治性前列腺切除术后需放疗且被认为适合无、短期或长期ADT的患者中,未见加用ADT改善长期结局的证据。
  • 作者认为未来研究应聚焦转移风险更高、更急需改善的患者。

研究设计与样本

  • RADICALS-HD为随机试验,三向比较根治性前列腺切除术后放疗联合无(None)、6个月(Short)或24个月(Long)ADT。
  • 2007年至2015年间共492例参与者随机分入三组:无ADT组166例、短期组164例、长期组162例。
  • 主要终点为无转移生存(MFS),次要终点包括无远处转移、总生存和非方案ADT启动;样本量由两两比较确定,分析采用标准时间-事件方法和意向性治疗原则。

主要发现

  • 随机时中位年龄66岁;手术Gleason评分<7者64例(13%)、3+4者229例(47%)、4+3者127例(26%)、8+者72例(15%);T3b者112例(23%),T4者5例(1%)。
  • 中位随访9.0年,共报告89例MFS事件(无ADT组32例、短期组31例、长期组26例),总体MFS无差异(logrank p=0.98)。
  • 长期对比无ADT的风险比=0.948(95%CI 0.54-1.68)。
  • 10年后无转移生存:无ADT组80%、短期组77%、长期组81%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 三向随机化未按常规统计效能水平设计评估,但提供了公平比较。
  • 作者认为未来研究应聚焦转移风险更高、更急需改善的患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: The use and duration of androgen deprivation therapy (ADT) with postoperative radiotherapy (RT) have been uncertain. RADICALS-HD compared adding no ("None"), 6-months ("Short"), or 24-mo ("Long") ADT to study efficacy in the long term. METHODS: Participants with prostate cancer were indicated for postoperative RT and agreed randomisation between all durations. ADT was allocated for 0, 6, or 24 mo. The primary outcome measure (OM) was metastasis-free survival (MFS). The secondary OMs included freedom from distant metastasis, overall survival, and initiation of nonprotocol ADT. Sample size was determined by two-way comparisons. Analyses followed standard time-to-event approaches and intention-to-treat principles. KEY FINDINGS AND LIMITATIONS: Between 2007 and 2015, 492 participants were randomised one of three groups: 166 None, 164 Short, and 162 Long. The median age at randomisation was 66 yr; Gleason scores at surgery were as follows: <7 = 64 (13%), 3+4 = 229 (47%), 4+3 = 127 (26%), and 8+ = 72 (15%); T3b was 112 (23%); and T4 was 5 (1%). The median follow-up was 9.0 yr and, with MFS events reported for 89 participants (32 None, 31 Short, and 26 Long), there was no evidence of difference in MFS overall (logrank p = 0.98), and, for Long versus None, hazard ratio = 0.948 (95% confidence interval 0.54-1.68). After 10 yr, 80% None, 77% Short, and 81% Long patients were alive without metastatic disease. The three-way randomisation was not powered to conventional levels for assessment, yet provides a fair comparison. CONCLUSIONS AND CLINICAL IMPLICATIONS: Long-term outcomes after radical prostatectomy are usually favourable. In those indicated for postoperative RT and considered suitable for no, short-term, or long-term ADT, there was no evidence of improvement with addition of ADT. Future research should focus on patients at a higher risk of metastases in whom improvements are required more urgently.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Parker CC, Clarke NW, Cook AD, et al. Randomised Trial of No, Short-term, or Long-term Androgen Deprivation Therapy with Postoperative Radiotherapy After Radical Prostatectomy: Results from the Three-way Comparison of RADICALS-HD (NCT00541047). Eur Urol. 2024. PMID: 39217077. doi:10.1016/j.eururo.2024.07.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。